Condition: B-cell Malignancy · Non-Hodgkin Lymphoma · Mantle Cell Lymphoma · Sponsor: BeiGene
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
This description comes directly from the study's public registry record.
BeiGene · 1.877.828.5568 · clinicaltrials@beigene.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical University | Bengbu, Anhui, China | Recruiting |
| Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Chao Yang Hospital,Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial Peoples Hospital Huifu Branch | Guangzhou, Guangdong, China | Recruiting |
| The Peoples Hospital of Guangxi Zhuang Autonomous Region | Nanning, Guangxi, China | Recruiting |
| Nanyang Central Hospital | Nanyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital of Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05294731